Skip to main content
Quest Diagnostics

Targeted Sequencing and In Vitro Splice Assays Shed Light on ABCA4-Associated Retinopathies Missing Heritability

Targeted Sequencing and In Vitro Splice Assays Shed Light on ABCA4-Associated Retinopathies Missing Heritability

Authors: Corradi Z, Khan M, Hitti-Malin R, Mishra K, Whelan L, Cornelis SS; ABCA4-Study Group; Hoyng CB, Kämpjärvi K, Klaver CCW, Liskova P, Stohr H, Weber BHF, Banfi S, Farrar GJ, Sharon D, Zernant J, Allikmets R, Dhaenens CM, Cremers FPM

Citation: HGG Adv. 2023 Sep 12:100237. doi: 10.1016/j.xhgg.2023.100237. Online ahead of print.

Specialties: Genetics, Oncology

Disclaimer: One or more of the authors of this publication were employed at the time by BluePrint Genetics, a subsidiary of Quest Diagnostics.

Related content

Publication
A genetic and clinical study of individuals with nonsyndromic retinopathy

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.